Beam Therapeutics (BEAM) Q1 2025 Earnings
How Did BEAM Stock React to Q1 2025 Earnings?
S&P 500 over the same 30 days: +7.22%.
Did BEAM Beat Earnings? Q1 2025 Results
No. Beam Therapeutics reported Q1 2025 earnings of $-1.24 a share on May 6, 2025, missing the $-1.17 consensus estimate by 5.9%. Revenue was $7.5M against a $14.7M estimate.
Beam Therapeutics delivered a disappointing first quarter for fiscal 2025, missing on both the top and bottom lines as heavy clinical investment weighed on results. The company reported a loss of $1.24 per share, coming in 5.86% below the consensus estimate of $1.17, while revenue of $7.47 million fell sharply short of the $14.68 million analysts had anticipated, a 49.13% miss despite being essentially flat year over year, up just 0.8% from $7.41 million in Q1 2024. The primary driver of the widening net loss, which reached $109.27 million compared to $98.67 million a year earlier, was a surge in R&D spending to $98.82 million as Beam advanced multiple programs simultaneously. The quarter's most consequential development was positive initial clinical data for BEAM-302 in alpha-1 antitrypsin deficiency, which supported a $500.00 million oversubscribed financing that lifted cash to $1.22 billion, a runway management says extends into 2028 and covers key milestones including updated BEAM-302 data expected at a medical conference in the second half of 2025.
- Advancement of multiple clinical-stage programs driving increased R&D investment
- License and collaboration revenue remained stable year-over-year
- $500 million oversubscribed registered direct financing strengthened balance sheet
“Beam has had a tremendous start to what we anticipate will be a transformative year. In March, we achieved a historic milestone with BEAM-302, delivering the first-ever clinical genetic correction of a disease-causing mutation for alpha-1 antitrypsin deficiency. Building on this momentum, we have swiftly advanced the program—initiating the fourth cohort of Part A of the Phase 1/2 BEAM-302 study and securing U.S. FDA clearance for our investigational new drug application, positioning us for continued rapid progress.”
Beam Therapeutics CEO, on the earnings call
What Was Beam Therapeutics's Outlook in Q1 2025?
Beam expects its cash, cash equivalents and marketable securities of $1.2 billion as of March 31, 2025, including net proceeds from the recent $500 million financing, to fund anticipated operating expenses and capital expenditure requirements into 2028. Key milestones include: continued dose escalation in Part A of the BEAM-302 Phase 1/2 trial with further data expected at a medical conference in H2 2025; dosing the first patient in Part B of the BEAM-302 trial (including AATD patients with mild to moderate liver disease) in H2 2025; continued dosing in the Phase 1/2 trial of BEAM-301 for GSDIa; dosing 30 patients in the BEACON Phase 1/2 trial of BEAM-101 in SCD by mid-2025; presentation of updated BEACON data at EHA 2025 in June; and initiation of a Phase 1 healthy volunteer trial of BEAM-103 (ESCAPE monoclonal antibody) by year-end 2025.
BEAM YoY Financials
| Metric | Q1 2025 | Q1 2024 | Year over year |
|---|---|---|---|
| Revenue | $7.5M | $7.4M | +0.8% |
| Operating Income | −$119.3M | −$139.6M | −14.6% |
| Net Income | −$109.3M | −$122.4M | −10.7% |
Figures from SEC filings and company reports. Not investment advice.